GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OTCPK:HLBBF) » Definitions » Profitability Rank

H. Lundbeck AS (H. Lundbeck AS) Profitability Rank : 7 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Profitability Rank?

H. Lundbeck AS has the Profitability Rank of 7.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

H. Lundbeck AS's Operating Margin % for the quarter that ended in Mar. 2024 was 24.17%. As of today, H. Lundbeck AS's Piotroski F-Score is 7.


Competitive Comparison of H. Lundbeck AS's Profitability Rank

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's Profitability Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Profitability Rank distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Profitability Rank falls into.



H. Lundbeck AS Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

H. Lundbeck AS has the Profitability Rank of 7.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

H. Lundbeck AS's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=186.303 / 770.868
=24.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

H. Lundbeck AS has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

H. Lundbeck AS operating margin has been in a 5-year decline. The average rate of decline per year is -9.5%.

4. Consistency of the profitability

5. Predictability Rank


H. Lundbeck AS Profitability Rank Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS (H. Lundbeck AS) Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.